Romosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series
Open Access
- 8 December 2025
- journal article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (2)
Abstract
Introduction: Discontinuation of denosumab can lead to a rebound increase in bone resorption, which may result in multiple vertebral fractures. Current guidelines recommend retreatment with denosumab or administration of zoledronate in this setting. Materials and methods: We report a series of 4 patients who developed vertebral fractures following denosumab withdrawal and were subsequently treated with romosozumab, a dual-action agent with anabolic and antiresorptive properties. Results: All patients showed progressive improvement in BMD and microarchitecture, with suppression of bone turnover markers and no new clinical fractures during treatment and follow-up. Discussion: Although limited by the uncontrolled design and small sample size, these observations suggest that romosozumab might be considered as a potential therapeutic approach for selected patients with post-denosumab rebound fractures.Keywords
This publication has 10 references indexed in Scilit:
- Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal womenJournal of Bone and Mineral Research, 2024
- Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-reportJoint Bone Spine, 2024
- Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world studyJBMR Plus, 2024
- Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational studyJBMR Plus, 2024
- Denosumab Discontinuation and the Rebound Phenomenon: A Narrative ReviewJournal of Clinical Medicine, 2021
- Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case reportBone Reports, 2020
- Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTSThe Journal of Clinical Endocrinology & Metabolism, 2020
- Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM studyOsteoporosis International, 2017
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled studyThe Journal of Clinical Pharmacology, 2013
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009